
Sensex fell 48.78 points, or 0.07 per cent, to 72,480.29, and Nifty declined 95.75 points, or 0.42 per cent, to 22,620.45 on Wednesday, 30 September, extending losses for a third straight session. Late selling in metal and pharma shares erased intraday gains. Elevated crude prices, global bond yields and persistent foreign fund outflows kept sentiment cautious. Foreign Institutional Investors sold equities worth Rs 9,980.22 crore on Tuesday, 29 September.

For September, the Sensex lost 5.81 per cent and the Nifty fell 6 per cent. National Herald India reported that Brent crude rose 0.54 per cent to USD 103.10 a barrel, while the US 10-year Treasury yield touched 5.293 per cent. Livemint added that 10 Nifty 50 stocks, including Bajaj Finserv (down 14.35 per cent), Infosys (13 per cent) and TCS (12.4 per cent), posted double-digit losses in September. The Nifty 50 is down 13.5 per cent year-to-date, positioning for its biggest annual decline since 2011.
Both sources report the same market data, but National Herald India leads with the day's closing levels and intraday swings, quoting analysts on cautious sentiment and global macro overhangs. Livemint leads with a stock-level breakdown, naming Bajaj Finserv, Infosys and TCS as the worst hit and framing the month as a deepening sell-off with a year-to-date decline. National Herald India is neutral-report with analyst quotes, Livemint is also neutral-report but with a sharper focus on individual losers and the annual comparison. The difference is one of entry point: National Herald India gives a trader's close-of-play view, Livemint gives a long-term investor's scorecard. The next concrete figure to watch is the Nifty 50's year-end performance, which Livemint notes is on track for its worst since 2011.
Both sources are neutral-report on this story.
Coverage: 2 sources, 2 neutral
Sources (2): nationalheraldindia.com (neutral report), livemint.com (neutral report)
This brief was synthesised by AI from the 2 sources linked above, so one read covers every framing they carry. Methodology and corrections.